ResearcherInsermNo recent work listed
Sylvain Manfrédi
Matched on ORCID iD 0000-0001-7530-4621; OpenAlex author ID A5031132493. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 5
- Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
- Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. Co-author DOI 10.3390/cancers14071675↗
- [Epidemiology of pancreatic cancer]. First author DOI 10.1016/j.bulcan.2017.11.004↗
- Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study. Last author DOI 10.1097/cej.0000000000000303↗
- FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Co-author DOI 10.1245/s10434-014-3898-9↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Côme Lepage · 3 shared papers, 2018–2023 · strength 0.40
- Paper Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. DOI 10.3390/cancers14071675↗
- Paper Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. DOI 10.21037/jgo-22-946↗
- Paper [Epidemiology of pancreatic cancer]. DOI 10.1016/j.bulcan.2017.11.004↗
- Anne‐Marie Bouvier · 3 shared papers, 2017–2022 · strength 0.36
- Paper Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. DOI 10.3390/cancers14071675↗
- Paper [Epidemiology of pancreatic cancer]. DOI 10.1016/j.bulcan.2017.11.004↗
- Paper Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based… DOI 10.1097/cej.0000000000000303↗
- François Ghiringhelli · 2 shared papers, 2022–2023 · strength 0.28
- Antoine Drouillard · 2 shared papers, 2018–2023 · strength 0.24
- Isabelle Trouilloud · 2 shared papers, 2015–2023 · strength 0.16
- Paper Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. DOI 10.21037/jgo-22-946↗
- Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
- Jean‐Baptiste Bachet · 2 shared papers, 2015–2023 · strength 0.16
- Paper Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. DOI 10.21037/jgo-22-946↗
- Paper FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational coh… DOI 10.1245/s10434-014-3898-9↗
- Olivier Facy · 1 shared paper, 2022 · strength 0.16
- Valérie Jooste · 1 shared paper, 2022 · strength 0.16
- Noelle K. LoConte · 1 shared paper, 2023 · strength 0.12
- Jerome F. Cros · 1 shared paper, 2023 · strength 0.12
- David Piquemal · 1 shared paper, 2023 · strength 0.12
- Christophe Tournigand · 1 shared paper, 2023 · strength 0.12
- Emmanuelle Kempf · 1 shared paper, 2023 · strength 0.12
- Émilie Soularue · 1 shared paper, 2023 · strength 0.12
- Cindy Canivet · 1 shared paper, 2023 · strength 0.12
- Barbara Bournet · 1 shared paper, 2023 · strength 0.12
- Adelaida Garcia-Velasco · 1 shared paper, 2017 · strength 0.08
- Jean‐Frédéric Blanc · 1 shared paper, 2015 · strength 0.04
- David Malka · 1 shared paper, 2015 · strength 0.04
- Christelle de la Fouchardière · 1 shared paper, 2015 · strength 0.04
- António Sá Cunha · 1 shared paper, 2015 · strength 0.04
- Lysiane Marthey · 1 shared paper, 2015 · strength 0.04
- Julien Taı̈eb · 1 shared paper, 2015 · strength 0.04
- Romain Coriat · 1 shared paper, 2015 · strength 0.04
- Éric François · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.